|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer cells grown as spheroids are uniquely receptive to IL-6-dependent induction of hepcidin by tumor-associated fibroblasts, since IL-6 does not induce hepcidin in cells grown as monolayers.
|
29695834 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer cell lines T47D and MCF7 were exposed to IL-6, the expression of PIM1 was examined by quantitative real-time PCR (qRT-PCR) and western blot.
|
30989585 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 is able to inhibit growth of breast carcinoma cells in culture.
|
10813718 |
2000 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 modulates immune response, estrogen production, and growth pathways in breast cancer.
|
19435922 |
2009 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 production in human breast cancer cells was dependent on their TG2 expression level.
|
21967801 |
2011 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-6 inhibited E2-induced GREB1 transcription activity and GREB1 mRNA expression.
|
23056300 |
2012 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-6, IL-12 and LCN2 were significantly higher in control obese and breast cancer group than their relevant lean controls (p<0.05), while NUCKS-1 mRNA expression was significantly higher in the breast cancer group compared to the other groups (p<0.05).
|
24568505 |
2014 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-6 mediated activation of Stat3 is a major signaling pathway in the process of breast cancer metastasis.
|
25213863 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis.
|
25697898 |
2015 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL6 and CCL5 gene expression are basal breast cancer specific, whereas high gene expression of GP130 was observed in luminal A/B.
|
26173622 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer.
|
27879265 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL6 blockade potentiates the anti-tumor effects of γ-secretase inhibitors in Notch3-expressing breast cancer.
|
29027990 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 <i>Trans</i>-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells <i>via</i> Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer.
|
29326716 |
2017 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer.
|
29482885 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression.
|
30134951 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-6 levels in the serum of 60 breast cancer patients were found to be increased in 27% (16/60) compared to 2% (1/50) in a control group.
|
9770334 |
1998 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accelerated IL-6 secretion following RB inactivation in an RB-intact luminal-type breast cancer cell line MCF-7 promoted a positive feed forward loop between IL-6 and STAT3 driving tumor growth and endocrine therapy resistance.
|
28481867 |
2017 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although polymorphisms within the IL1 gene cluster do not seem to influence breast cancer risk or phenotype, presence of the -174C IL6 allele increases the risk of breast cancer in Caucasian women in a dose-dependent fashion.
|
16115908 |
2005 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among the isolated compounds, 2 and 5 showed significant inhibitory activities toward the LPS-induced production of IL-6 in the human acute monocytic leukemia cell line THP-1, and 7 displayed cytotoxicity against MCF-7, PC9, A549, and breast cancer stem cells (MCF-7-Oct4-GFP) with IC<sub>50</sub> values of 5.2, 5.6, 7.8, and 10 μM, respectively.
|
29648818 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
An IL-6 gene expression pattern induced by heterotypic interaction of breast cancer cells with osteoblasts in vitro is associated with a higher rate of bone metastasis in vivo.
|
22235336 |
2012 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Analysis of serum-free conditioned media from three breast cancer cell lines (MCF-7, SK-BR-3, and MDA-MB-231) expressing WT MMP-8 revealed elevated levels of IL-6 and IL-8.
|
23632023 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Areas covered: In this review, we focus on the role of leptin, adiponectin, autotaxin, and interleukin-6 in breast cancer initiation, progression, metastasis, and drug response.
|
30332900 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells.
|
11751408 |
2001 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bidirectional Cause-Effect Relationship Between Urinary Interleukin-6 and Mood, Irritation, and Mental Activity in a Breast Cancer Survivor.
|
30546293 |
2018 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both IL-6 (-597) GA and IL-6 (-174) GC heterozygous genotypes were found to be significantly associated with breast carcinoma (OR = 1.59, p = 0.024 and OR = 1.61, p = 0.022 respectively).
|
16464738 |
2005 |